×

OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST

desc
desc

SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the BREVAGen™ predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.

"As my patients age with me, it has become apparent that there is a significant need to manage the effects of menopause. Women are now living a third of their life beyond menopause, yet with menopause comes changes in health and heightened risks such as sporadic breast cancer which require greater vigilance in the care they receive," said Russell Stankiewicz, MD, FACOG, CCD, NMCP. "By seeking out and providing the most up-to-date healthcare options, we can help women understand and take more control of those risks. BREVAGen, which gives patients an accurate five-year and lifetime risk assessment for developing sporadic breast cancer, helps us understand each patient's risk so we can then develop personalized breast health and monitoring plans tailored to their specific risk and needs. This will help us reduce the incidence of advanced breast cancer cases we see and should help save lives."

BREVAGen is a clinically validated predictive risk test that more accurately identifies a woman's unique risk of developing sporadic, estrogen-positive breast cancer. BREVAGen examines a woman's clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient's personalized five-year and lifetime risk of developing breast cancer.1 BREVAGen is supplied by Phenogen Sciences, a subsidiary of Genetic Technologies Limited (NASDAQ: GENE). For more information about BREVAGen at OB/GYN Associates of Lewisburg, P.C., contact the office at (570) 523-8700.

How BREVAGen Works





The BREVAGen predictive risk test is administered in a physician's office using a simple, non-invasive "oral-swab." Following analysis in a CLIA-certified laboratory, physicians receive a comprehensive genetic risk prediction report to review with the patient.

The patient's risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNPs (single nucleotide polymorphisms), with factors that comprise the patient's clinical and reproductive history including current age, age at menarche, age at live first birth and race/ethnicity.

The BREVAGen test provides five-year and lifetime predictive risk assessments to more accurately evaluate the patient's risk for developing sporadic breast cancer, regardless of family history or previous indeterminate test results.

Clinically Validated

BREVAGen was proven superior in determining breast cancer risk compared to Gail score alone.1 Utilizing data from the U.S. Women's Health Initiative (WHI) Clinical Trial, 3,300 women underwent breast cancer assessment utilizing the BREVAGen test. Of those 3,300 women, 1,664 were diagnosed with breast cancer and 1,636 were in the breast cancer-free control group. BREVAGen test results support current American Cancer Society (ACS), www.cancer.org, American Society of Clinical Oncology (ASCO), www.asco.org, and The National Comprehensive Cancer Network (NCCN), www.nccn.org, guidelines for prevention and early detection of breast cancer.2, 3

About OB/GYN Associates of Lewisburg

OB/GYN Associates of Lewisburg, P.C. is a private, physician-owned medical practice, specializing in obstetrics and gynecology. Established in 1995, the practice offers a wide-ranging list of healthcare services for women of all ages, including obstetrical and prenatal care, high-risk prenancy, infertility issues, and all aspects of gynecological surgery.

As the area leaders for prenatal/pregnancy care, our board certified physicians and certified nurse midwives collectively provide more than 77 years of obstetrical experience for you and your baby. We also have the expertise, and collaborate with maternal fetal medicine physicians, to provide comprehensive care for high-risk pregnancies.

Our physicians perform a full spectrum of gynecological surgeries, and are expert in the latest and most advanced minimally–invasive GYN surgeries. For your convenience, we are able to perform your surgery at Evangelical Community Hospital and Sunbury Community Hospital. In addition, new technology now allows us to perform certain procedures in the comfort and convenience in our office setting instead of the more traditional operating room.

Our dedicated staff of nurses, office and billing personnel work in concert with the provider staff to also offer you one-on-one patient education opportunities, medication and pharmaceutical information, and to answer all of your healthcare, billing and insurance questions. For more information, call (570) 523-8700 or visit www.OBGYNAssociatesOfLewisburg.com.

About Phenogen Sciences

Phenogen Sciences, the U.S. subsidiary of Australia-based Genetic Technologies Limited, is a pioneer in personalized healthcare. Phenogen offers novel predictive testing and assessment tools that help physicians proactively manage women's health risks.

Phenogen's lead product, BREVAGen, is a clinically validated test that combines a woman's clinical history of estrogen exposure with her genetic predisposition to its effects - more accurately categorizing her personal risk for developing breast cancer. For more information, visit www.phenogensciences.com.

About Genetic Technologies Limited

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The company has operations in Australia and the U.S. and is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. For more information, please visit www.gtglabs.com.

1 Mealiffe M, Stokowski RP, Rhees, BK, et al. J Nat Cancer Inst. 2010;102(21):1618-1627.

2 Saslow D, Boetes C, Burke W, et al. CA Cancer J Clin. 2007;57(2):75-89.

3 Visvanathan K, Chlebowski RT, Hurley P, et al. J Clin Oncol. 2009;27(19):3235-3258.

4 Breast Cancer Overview. American Cancer Society. Accessed 3/14/12 at http://www.cancer.org/cancer/breastcancer/overviewguide/breast-cancer-overview?docSelected=breast-cancer-overview-key-statistics

5 DeSantis C, Siegel R, Bandi P, Jemal A. CA: A Cancer Journal For Clinicians. 2011;61: 409-418

Additional Information

About Breast Cancer

  • Approximately one in eight women will get breast cancer4
  • 70% to 80% of those who get breast cancer do not have familial risk indicators2
  • Risk of invasive vs. non-invasive breast cancer is approximately four times greater in women age 40-645
  • Approximately 75% of all breast cancer is estrogen-positive and, if detected early, can be effectively treated with five-year survival rates of over 95%

Breast Cancer Demographics

According to the American Cancer Society, breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer.4 According to the 2010 breast cancer demographics there are:

  • Approximately 207,000 new cases diagnosed each year4
  • Of the 207,000 new cases, about 54,000 are non-invasive forms of breast cancer that have been diagnosed early4
  • Approximately 40,000 deaths related to breast cancer in women, annually4

BREVAGen reclassified 64% of above average Gail risk subjects1

BREVAGen reclassified 64% of Gail scores above average risk subjects as either high or low risk for development of hormone-dependent breast cancer. Furthermore, the BREVAGen test reclassified the breast cancer risk for 33% of the total 3,300 trial subjects.1

About BREVAGen™

The first product in Phenogen Science's portfolio, BREVAGen™ is a predictive risk test for sporadic, hormone-dependent breast cancer. The BREVAGen test combines a woman's clinical history of estrogen exposure with the presence of identified genetic markers to determine her five-year and lifetime risk for developing breast cancer. For women whose clinical profile indicates prolonged estrogen exposure, BREVAGen helps to provide a more accurate risk assessment for estrogen-positive breast cancer. The test results assist physicians in developing a personalized care path toward managing each woman's risk of developing breast cancer with greater precision than ever before.

  • Non-invasive, easy-to-use predictive risk assessment test
  • The first genetic risk prediction test to have been validated in a large-scale, peer-reviewed, case-controlled study1
  • Recent studies demonstrate that 64% of women who have above average risk of prolonged estrogen exposure were either reclassified above the guidelines for high risk management or below the general population risk when compared to clinical risk factors alone1
  • Supports existing industry guidelines for the prevention of estrogen-positive breast cancer2,3

Click here for BREVAGen B-roll/video:

Photos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=20653

http://www.globenewswire.com/newsroom/prs/?pkgid=20654

CONTACT:Andrea Preston Kovak-Likly Communications (203) 762-8833 or APreston@KLCpr.comSource:Genetic Technologies Group